AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00793715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive laparotomy with temporary abdominal closure
Description: Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
Study NCT00793715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous puncture with placement of abdominal catheter
Description: Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
Study NCT05066802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant modified FOLFIRINOX
Description: oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
Study NCT03112642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic block [0.35% marcaine]
Description: In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.
Study NCT03112642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic block [0.35% marcaine]
Description: In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.
Study NCT03112642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Braun DIG-R-C Stimuplex Blockade Monitor System
Description: The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
Study NCT00073697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
Study NCT03514784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB-12 with LGG (Higher Dose)
Description: BB-12 with LGG - Higher Dose (10 billion CFUs)
Study NCT03514784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT03514784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB-12 with LGG (Lower Dose)
Description: BB-12 with LGG - Lower Dose (1 billion CFUs)
Study NCT01975909 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
Study NCT00073697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
Study NCT00073697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escitalopram plus IPT
Description: Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
Study NCT01975909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
Study NCT00567892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)
Study NCT00567892 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)
Study NCT02265926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N95 mask
Description: N95 mask material used to cover aperture of Hans Rudolph mask
Study NCT03537131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG Oral Tablet
Description: taken once a day
Study NCT03252561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Transversus Abdominis Plane (TAP) bock
Description: Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
Study NCT03252561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthetic infiltration of laparoscopic port sites
Description: Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
Study NCT02256436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study NCT02256436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: IV infusion
Study NCT02256436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinflunine
Description: IV infusion
Study NCT02256436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: IV infusion
Study NCT01831102 — intervention group
Intervention type: OTHER
Intervention: none- observational study
Study NCT01517958 — intervention group
Intervention type: OTHER
Intervention: Respiratory Distress Group
Description: Diagnostic lung ultrasound.
Study NCT01517958 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: Lung ultrasound
Study NCT01704274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dose GTN 0.0285 mg/hr
Description: Low Dose GTN
Study NCT00862329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein-enriched diet
Description: Subjects consume for 9 days a supplement of 30g/d of casein
Study NCT01704274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dose GTN 0.057 mg/hr
Description: High Dose GTN
Study NCT01704274 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00100308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin
Description: Low-dose continuous-infusion, 500 units/hour per seven days
Study NCT00100308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline placebo
Study NCT00633347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antagonist GnRH Cetrotide
Description: Cetrotide 0.25 mg. daily/ 7 days
Study NCT03095391 — intervention group
Intervention type: DEVICE
Intervention: VFI
Description: The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Study NCT03095391 — intervention group
Intervention type: DEVICE
Intervention: Iohexol
Description: Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Study NCT01909154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell therapy
Description: Stem cells administration locally
Study NCT00862329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk soluble protein-enriched diet
Description: Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
Study NCT04246060 — intervention group
Intervention type: DRUG
Intervention: Cysteamine Bitartrate
Description: ERT
Study NCT01829516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal oxytocin
Study NCT01829516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo
Study NCT00156533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: 10 mg of Zolpidem
Study NCT00156533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 10 mg of Zolpidem
Study NCT00156533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study NCT03577743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: -bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
Study NCT00633347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist GnRH Acetate Triptoreline
Description: Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
Study NCT02892760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Brace
Description: C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
Study NCT04450147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi/Qigong vs. Walking/Stretching
Description: Both interventions can be thought of as a form of movement and exercise.
Study NCT04083209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid counseling
Description: The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
Study NCT04027985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: inesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
Study NCT04027985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hand rehabilitation program
Description: In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
Study NCT00862329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein and milk soluble proteins-enriched diet
Description: Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
Study NCT00862329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy proteins-enriched diet
Description: Subjects consume for 9 days a supplement of 30g/d of soy protein
Study NCT04027985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand rehabilitation program
Description: In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
Study NCT04027985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
Study NCT04794244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASGE-FABES Program
Description: In the control group study, pretest-posttest and experimental design with repeated measurements were used in randomized groups. An overweight and obese adolescent constituted the sample of 250 (125-experiment, 125-control) of the study. Research data Socio-Demographic Features Information Form, Adolescent Nutrition Information Scale, Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Healthy Lifestyle Choice Scale for Adolescents, Beck Anxiety Scale, Daily Food Consumption Form, Beverage Consumption Form, collected using. Data are saved before and after application. ASGEFABES PROGRAM was applied to the experimental group for 10 weeks. Measurements after the training program were collected in four measurements: 1st week, 6th and 12th months.
Study NCT00439218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: 500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
Study NCT04220983 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MR-Guided Prostate SBRT
Description: Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
Study NCT00310037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT03431415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Segmentectomy, Lobectomy or Bilobectomy
Description: Lung Cancer Anatomical Resection
Study NCT03431415 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
Study NCT03065166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Raisin Treatment
Description: Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
Study NCT03065166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisin Treatment
Description: Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
Study NCT03065166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bagel Control
Description: Subjects will consume 95g of whole wheat bagel during a single intervention time point.
Study NCT03065166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bagel Control
Description: Subjects will consume 95g of whole wheat bagel during a single intervention time point.
Study NCT03124524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate/dienogest
Description: oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
Study NCT03124524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinylestradiol and drospirenone
Description: oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
Study NCT04249466 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: During this consult, several parameters will be measured :~* nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~* demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~* patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage.
Study NCT04397757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma
Description: 2 units of COVID-19 convalescent plasma compatible with their blood type
Study NCT03534466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby treadmill
Description: The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
Study NCT03534466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical rehabilitation training
Description: Suitable for general physical rehabilitation training of all infants with cerebral palsy.
Study NCT03534466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical rehabilitation training
Description: Suitable for general physical rehabilitation training of all infants with cerebral palsy.
Study NCT03893994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Stretching exercises will be applied 6 days a week, 30sec / 5 reps
Study NCT02059174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1293
Description: MK-1293 0.4 units/kg administered subcutaneously
Study NCT02059174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-Lantus™
Description: EU-Lantus™ 0.4 units/kg administered subcutaneously
Study NCT02059174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog™
Description: Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
Study NCT01768039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study NCT01768039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04371757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α1-adrenergic block
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
Study NCT04371757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
Study NCT01309646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV+Hib
Description: Intramuscular, 3 doses
Study NCT01309646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ IPV
Description: Intramuscular, 3 doses
Study NCT01309646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: Intramuscular, 3 doses
Study NCT01309646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular, 3 doses
Study NCT01309646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: Intramuscular, 3 doses
Study NCT01309646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Oral, 2 doses
Study NCT01309646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Oral, 2 doses
Study NCT02143336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcuticular suture
Study NCT02143336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin staples